Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data ...

Shares of Tvardi Therapeutics TVRD nosedived 83.9% on Monday after the company provided a disappointing update following an ...

Beyond its initial phase II trial results, stroke therapy developer Argenica has identified a clear path forward based on new ...

Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat ...

The IMF’s latest intervention underscores the growing concern that non-bank risks are migrating beyond the reach of ...

Indian Institute of Technology Delhi has announced the second batch of its Certificate Programme in Applied Data Science & Artificial Intelligence: From Fundamentals to Deployment. The programme will ...

On a mission to lighten the workload for data scientists, Google LLC’s cloud division today announced a wave of new artificial intelligence tools designed to help them build the next generation of AI ...

Tvardi Therapeutics shares were 30% lower, at $7.19, in premarket trading after the company said its phase 2 study for TTI-101 didn't meet its goals. TTI-101 is a small molecule therapy targeting ...

Anavex Life Sciences (AVXL) stock gains as the company reports success in a Phase 2 trial for its experimental schizophrenia therapy NAVEX 3-71. Read more here.

InfluxData is releasing InfluxDB 3.5 for both Core and Enterprise, along with introducing updates to the new Explorer UI that make it easier to save, organize, and query data. According to the company ...